pharma · Chronic Spontaneous Urticaria · Asthma
Novartis India
Novartis Pharmaceuticals
Novartis Pharmaceuticals is a pharma organization headquartered in CN. Primary therapeutic focus areas include Chronic Spontaneous Urticaria, Asthma, Systemic Lupus Erythematosus, Breast Cancer, Multiple Sclerosis. NovaP
Mumbai, IN HQ
1996 Founded
2,240 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Mumbai, IN
- Founded
- 1996
- Employees
- 2,240
- Programs
- 341
- Drugs
- 317
- Patents
- 0
ASCIMINIB HYDROCHLORIDE, ASCIMINIB
Phase 3 · small molecule · Chronic Myelogenous Leukemia in chronic phase (CML-CP)
ASCIMINIB HYDROCHLORIDE, ASCIMINIB for Chronic Myelogenous Leukemia in chronic phase (CML-CP) is a Phase 3 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code CABL001A2302
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Chronic Myelogenous Leukemia in chronic phase (CML-CP)
- Status
- active
- Trials
- 1